








asof: 2026-09-17
The Buy call and the core domestic defence/space growth thesis persisted, with the order pipeline expanding from BTS ₹650–665 Cr and EMS ₹763 Cr to a ₹1,952 Cr book (BTS ₹959 Cr, +47% YoY) by September 2026, but the margin recovery ran a year behind schedule: the 13–15% margin promised for FY26 is now only targeted in FY28, after BTS/EMS mix gains lifted EBITDA margin back to 12.7% in Q2FY27 from 7.1% in Q2FY26. The narrative also shifted from a near-term FY26 rebound (H2FY26 strength, margin guidance, moderating overseas losses, European/Canadian recovery) to a multi-year compounding story (FY27E revenue ₹1,240 Cr, FY28E ₹1,587 Cr/EPS ₹87.4, 20–22% medium-term BTS margins, semiconductor equipment toward US$45–50 Mn, EW exports and a satellite-payload facility), even though the FY26 revenue-implied (FY27E at 25–30% growth) margin sat below the originally guided 13–15%. Headwinds moved from external factors (Europe macro, overseas losses, Canadian divestment) to internal execution and balance-sheet constraints (component shortages with 40–50-week PCB lead times, raw-material inflation, BTS working capital and execution risk, and borrowing headroom largely used up, prompting a ₹500 → ₹1,000 Cr limit hike), yet the bullish tone never flagged that the stock had already fallen about 13.9% on the 2026-09-23 Buy.
Optimism that failed
4 broker calls · 2025-11-14 to 2026-11-06
No recorded CNBC-TV18 statements for this ticker.
No recorded management comments with an explicit designation and affiliation for this ticker.
Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.